Interest of Telemedicine in Primary Care in an Multidisability Population Institutionalized (TEDDY)
Visão geral do estudo
Status
Descrição detalhada
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Sabine Crestani, MD
- Número de telefone: +33 05 67 77 81 61
- E-mail: crestani.s@chu-toulouse.fr
Locais de estudo
-
-
-
Montauban, França, 82 000
- FAM la Vitarelle
-
Contato:
- Dounia Akrouh
- Número de telefone: +33 05 63 20 35 35
- E-mail: dounia.akrouh@asei.asso.fr
-
Investigador principal:
- Dounia Akrouh
-
Montauban, França, 82 000
- MAS de Granès
-
Contato:
- Dounia Akrouh
- Número de telefone: +33 05 63 20 35 35
- E-mail: dounia.akrouh@asei.asso.fr
-
Investigador principal:
- Dounia Akrouh
-
Rieux-Volvestre, França, 31 310
- Mas Azure
-
Contato:
- Noémie Roussel
- Número de telefone: +33 06 75 17 21 76
- E-mail: noemie.roussel@asei.asso.fr
-
Contato:
- Germain Huc, MD
- Número de telefone: +33 05 81 44 10 01
- E-mail: germain.huc@asei.asso.fr
-
Investigador principal:
- Noémie Roussel
-
Subinvestigador:
- Germain Huc, MD
-
Toulouse, França, 31 059
- Larrey Hospital - Toulouse University Hospital
-
Contato:
- Sabine Crestani, MD
- Número de telefone: +33 05 67 77 81 61
- E-mail: crestani.s@chu-toulouse.fr
-
Contato:
- Virginie Woisard, PHD
- Número de telefone: +33 05 31 15 56 48
- E-mail: woisard.v@chu-toulouse.fr
-
Investigador principal:
- Sabine Crestani, MD
-
Subinvestigador:
- Virginie Woisard, PHD
-
Toulouse, França, 31200
- MAS Jean de la Fontaine
-
Contato:
- Anne Breuillaud
- Número de telefone: +33 05 34 25 55 66
- E-mail: anne.breuillaud@asei.asso.fr
-
Contato:
- Gauthier Forni
- Número de telefone: +33 07 65 56 88 66
- E-mail: gauthier.forni@asei.asso.fr
-
Investigador principal:
- Anne Breuillaud
-
Subinvestigador:
- Gauthier Forni
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Patients aged ≥ 18 years living in a medical institution (MAS type, FAM from the ASEI network)
- Indication of a medical swallowing assessment in hospital
- Person affiliated to or beneficiary of a social security system.
- Free, informed and written consent signed by the participant or their guardian
Exclusion Criteria:
- Participation in another research including a period of exclusion still ongoing
- non-movable patient
- Pregnant woman, Woman of childbearing age without contraception
- any contraindication to nasofibroscopy and/or fluoroscopy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Patients with a deglutition disorder
All participants will have deglutition disorder.
|
The teleconsultation will be scheduled by the UVD programming IDE after contact by the structure team.
This teleconsultation will take place in the presence of the patient's care assistant as well as medical staff (IDE, occupational therapist, physiotherapist, speech therapist, etc.) from the institution and a doctor specializing in swallowing and a speech therapist for the university hospital.
The resident will do a food test under the eyes of CHU specialists.
The patient will be able to test several textures (more or less solid/liquid) prepared in the center in order to be more accurate in their daily life.
The meal will be in his familiar environment with his usual caregivers and tools.
The CHU team will be able to interact directly with the institution's staff in order to have all the information necessary to determine their conclusions : questions, details on the patient's degree of compliance, etc.
Treatment for swallowing disorders in the hospital sector consists of the patient coming to the university hospital or to a day hospital in order to carry out a swallowing assessment consisting of invasive examinations such as nasofibroscopy (NF), swallowing fluoroscopy (VFS) as well as eating a meal outside the patient's usual context, sometimes in the presence of other people foreign to the patient (source of distractibility and sometimes anxiety).
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Recommendations on food textures
Prazo: 1 month
|
Recommendations regarding food textures will be assessed using the IDDSI (International Dysphagia Diet Standardization Initiative) scale during the V1 telemedicine visit and the V2 outpatient visit 15 days later. This scale consists of 8 categories ranging from 0 ("liquid texture") to 7 ("normal texture"), which are used to assess patients' swallowing abilities. This scale will be used to assess the recommended solid-textured diet (IDDSI 3 to 7) and liquid-textured diet (IDDSI 0 to 4). The relevance between the results of the telemedicine and the outpatient visit will be assessed. |
1 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Evaluation of the satisfaction in the structures team
Prazo: 1 month
|
Satisfaction will be assessed using a satisfaction questionnaire to be completed by caregivers or paramedical staff at medical facilities for the first telemedicine assessment (V1), and then by caregivers accompanying the patient for the second assessment in a hospital setting (V2). It will consist of 8 questions answered on a scale ranging from 1 to 10. These questions will address satisfaction, the extent to which the consultation was tailored to the patient's needs and disability, the patient's dietary habits and the level of difficulty in conducting the consultation. A "free text comments" field will be available. |
1 month
|
|
Description of telemedicine treatment: feasibility
Prazo: 2 weeks
|
It will be assessed based on a description of how the teleconsultation (V1) is organized and the patient's care pathway, the presence of the usual caregiver during meals, a description of the difficulties encountered in evaluating feasibility and the level of discomfort during the food trial using the ECPA scale (Behavioral Scale for Non-Communicative Older Adults) (composite criterion). The last scale is based on the observation of the patient's behavior and assesses facial expressions, movements, interactions with others and behavior during the meal. The higher the score, the more severe is the pain. |
2 weeks
|
|
Description of telemedicine treatment: evaluation methods
Prazo: 2 weeks
|
It will be assessed based on the description of the remote ecological evaluation, the assessment of the validity of the telemedicine examination among the various stakeholders, and the collection of data on the type of IDDSI food textures before and after treatment (composite criterion).
|
2 weeks
|
|
Description of care in the hospital sector: feasibility
Prazo: 1 month
|
It will be assessed by describing the nature of the hospital visit (inpatient stay or outpatient visit), the presence of the usual caregiver, and the difficulties encountered in assessing feasibility, as well as the level of discomfort associated with medical procedures, using the ECPA scale (composite criterion).
|
1 month
|
|
Description of care in the hospital sector: evaluation methods
Prazo: 1 month
|
It will be assessed based on the description of the examinations and procedures performed under optimal conditions:
|
1 month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sabine Crestani, Service ORL - Hôpital Larrey
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- RC31/24/0427
- 2025-A02816-43 (Outro identificador: ID-RCB)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .